Industry News
Pharmaceutical Industry News
Millions of Eye Drop Bottles Recalled Over Contamination Concerns
The prescription drops are used to reduce inflammation after surgery or to treat irritation.
The forever more popular…
The forever more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again.
The three-part video podcast…
The three-part video podcast series features Londyn, 15, and Connor, 20, who live with phenylketonuria, or PKU, as they discuss their daily lives and disease management.
Bayer has addressed its need for a…
Bayer has addressed its need for a capital infusion under a deal to secure 3 billion euros ($3.4 billion) in equity from New York City asset manager Apollo, surrendering a minority, non-controlling stake in its
The third time is not the charm…
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics. The pair’s star-crossed cancer drug combination of camrelizumab and rivoceranib has been rejected by the FDA for the third time.
Sanofi has gained FDA approval of…
Sanofi has gained FDA approval of its subcutaneous version of Sarclisa, which can be delivered manually or by way of an on-body injector. The nod gives the multiple myeloma treatment a boost in its competition
AstraZeneca signed potential…
AstraZeneca signed potential billion-dollar licensing deals with CSPC and Sino Biopharm, Hengrui's Kaleira-partnered oral GLP-1 candidate reported obesity and diabetes phase 3 data from China, and biotech insiders decried certain U.S. lawmakers' scrutiny over Chinese
After several months of AbbVie…
After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings.
Two Telehealth Executives Sentenced for Scheme to Distribute Adderall
The Justice Department said Done Global’s clinicians signed prescriptions for the stimulant drug, which is used to treat A.D.H.D., every 30 seconds.
Bleeding disorder patient groups…
Bleeding disorder patient groups put Sobi, Roche and Novo Nordisk on the podium in 2025/2026's corporate reputation rankings from PatientView.
Aiming to streamline the…
Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. Kennedy Jr.’s Department of Health and Human Services is gearing up to draft a list of injuries believed to be
The surprising failure of…
The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling, while those of their competitors are soaring. The CARDIO-TTRansform study
In a first for the neurotoxin…
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines.
When launching a drug as big as…
When launching a drug as big as semaglutide, even as a generic, expectations are immense. Any fumble by a manufacturer can take a toll.
Novo Nordisk is running an…
Novo Nordisk is running an exhibition in central London designed to start a dialogue on obesity and help remove the stigma surrounding the condition.
BioNTech is on the verge of…
BioNTech is on the verge of returning to its oncology roots with potentially its first commercial cancer drug. Yet, to Chief Commercial Officer Annemarie Hanekamp, the upcoming launch is less of a standalone milestone and
The FDA took issue with multiple…
The FDA took issue with multiple claims describing Vyepti's efficacy listed on Lundbeck's healthcare provider webpage for the drug.
On the heels of a European…
On the heels of a European Commission probe into whether Sanofi “disparaged” one of its flu vaccine rivals in marketing its own shot, the EC is lining up a “market test” to solicit feedback on
Lawmakers Target the Power of Health Insurance Giants
UnitedHealth Group, CVS Health and Cigna are battling efforts to break up their control over prescription drugs.
How GLP-1s Feed Our Sick Culture
For women, they’re a depressingly rational choice.